$3.92
0.06[1.55%]
At close: Apr 26
$3.92
0[0.00%]
After Hours: 4:02PM EDT
G1 Therapeutics
(NASDAQ:GTHX)G1 Therapeutics Stock (NASDAQ:GTHX), Analyst Ratings, Price Targets, Predictions
G1 Therapeutics Inc has a consensus price target of $15.71, established from looking at the 34 latest analyst ratings. The last 3 analyst ratings were released from Needham, Needham, and Wedbush on April 12, 2024, February 28, 2024, and February 13, 2024. With an average price target of $9.33 between Needham, Needham, and Wedbush, there's an implied 138.10% upside for G1 Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Wedbush
JP Morgan
HC Wainwright & Co.
EF Hutton
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for G1 Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/12/2024 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 206.12% | Needham | Gil Blum | → $12 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 206.12% | Needham | Gil Blum | → $12 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2024 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 2.04% | Wedbush | David Nierengarten | $5 → $4 | Maintains | Outperform | Get Alert |
| 02/13/2024 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 206.12% | Needham | Gil Blum | $14 → $12 | Maintains | Buy | Get Alert |
| 01/24/2024 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 257.14% | Needham | Gil Blum | → $14 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 257.14% | Needham | Gil Blum | → $14 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 27.55% | Wedbush | David Nierengarten | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 10/06/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | — | JP Morgan | Anupam Rama | — | Downgrade | Neutral → Underweight | Get Alert |
| 08/03/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 27.55% | Wedbush | David Nierengarten | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 08/03/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 180.61% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 384.69% | EF Hutton | Tony Butler | → $19 | Reiterates | → Buy | Get Alert |
| 08/02/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 257.14% | Needham | Gil Blum | $18 → $14 | Maintains | Buy | Get Alert |
| 06/26/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 180.61% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 180.61% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 359.18% | Needham | Gil Blum | → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/04/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 180.61% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | → Buy | Get Alert |
| 05/04/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 104.08% | Raymond James | Dane Leone | $24 → $8 | Maintains | Outperform | Get Alert |
| 04/19/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 359.18% | Needham | Gil Blum | → $18 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | GTHX | Buy Now | G1 Therapeutics | $3.92 | 180.61% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for G1 Therapeutics (GTHX)?
The latest price target for G1 Therapeutics (NASDAQ: GTHX) was reported by Needham on April 12, 2024. The analyst firm set a price target for $12.00 expecting GTHX to rise to within 12 months (a possible 206.12% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for G1 Therapeutics (GTHX)?
The latest analyst rating for G1 Therapeutics (NASDAQ: GTHX) was provided by Needham, and G1 Therapeutics reiterated their buy rating.
When was the last upgrade for G1 Therapeutics (GTHX)?
The last upgrade for G1 Therapeutics Inc happened on January 30, 2023 when JP Morgan raised their price target to $10. JP Morgan previously had an underweight for G1 Therapeutics Inc.
When was the last downgrade for G1 Therapeutics (GTHX)?
The last downgrade for G1 Therapeutics Inc happened on October 6, 2023 when JP Morgan changed their price target from N/A to N/A for G1 Therapeutics Inc.
When is the next analyst rating going to be posted or updated for G1 Therapeutics (GTHX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of G1 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for G1 Therapeutics was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
Is the Analyst Rating G1 Therapeutics (GTHX) correct?
While ratings are subjective and will change, the latest G1 Therapeutics (GTHX) rating was a reiterated with a price target of $0.00 to $12.00. The current price G1 Therapeutics (GTHX) is trading at is $3.92, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.